Differential contribution of two serine residues of wild type and constitutively active β2-adrenoceptors to the interaction with β2-selective agonists

Hideo Kikkawa, Hitoshi Kurose, Masafumi Isogaya, Yoji Sato, Taku Nagao

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

1. We have studied the difference in receptor binding activity between partial and full β2-adrenoceptor agonists and the abilities of the agonists to interact with Ser204 and Ser207 in the fifth transmembrane region of the β2-adrenoceptor, amino acid residues that are important for activation of the β2-adrenoceptor. 2. In the binding study with [125I]-iodocyanopindolol, the K(i) values of (±)-salbutamol, (±)-salmeterol, TA-2005 and (-)-isoprenaline for the β2-adrenoceptor expressed in COS-7 cell membranes were 3340, 21.0, 12.0 and 904 nM, respectively. The β12 selectivity of these agonists was in the order of (±)-salmeterol (332 fold) > TA-2005 (52.8) > (±)-salbutamol (6.8) > (-)-isoprenaline (1.1), and the β3-/β2-adrenoceptor selectivity of these agonists was in the order of TA-2005 (150 fold) > (±)-salmeterol (88.6) > (±)-salbutamol (10.4) > (-)-isoprenaline (3.2). 3. The maximal activation of adenylyl cyclase by stimulation of the β1-, β2- and β3-adrenoceptors by TA-2005 was 32, 100 and 100% of that by (-)-isoprenaline, respectively, indicating that TA-2005 is a full agonist at the β2- and β3-adrenoceptors and a partial agonist at the β1-adrenoceptor. (±)-Salbutamol and (±)-salmeterol were partial agonists at both β1- (8% and 9% of (-)-isoprenaline) and β2- (83% and 74% of (-)-isoprenaline) adrenoceptors. 4. The affinities of full agonists, TA-2005 and (-)-isoprenaline, were markedly decreased by substitution of Ala for Ser204 (S204A) of the β2-adrenoceptor, whereas this substitution slightly reduced the affinities of partial agonists, (±)-salbutamol and (±)-salmeterol. Although the affinities of full agonists for the S207A-β2-adrenoceptor were decreased, those of partial agonists for the S207A-β2-adrenoceptor were essentially the same as for the wild type receptor. 5. The constitutively active mutant (L266S, L272A) of the β2-adrenoceptor had an increased affinity for all four agonists. The affinities of full agonists were decreased by substitution of Ser204 of the constitutively active mutant, whereas the degree of decrease was smaller than that caused by the substitution of the wild type receptor. Although the affinities of(±)-salbutamol and (±)-salmeterol for the S207A-β2-adrenoceptor were essentially the same as those for the wild type β2-adrenoceptor, the affinities of (±)-salbutamol and (±)-salmeterol for the constitutively active β2-adrenoceptor were decreased by substitution of Ser207. 6. These results suggest that Ser204 and Ser207 of the wild type and constitutively active β2-adrenoceptors differentially interacted with β2-selective agonists.

Original languageEnglish
Pages (from-to)1059-1064
Number of pages6
JournalBritish Journal of Pharmacology
Volume121
Issue number6
DOIs
Publication statusPublished - Aug 2 1997
Externally publishedYes

Fingerprint

Adrenergic Receptors
Serine
Albuterol
Isoproterenol
Iodocyanopindolol
COS Cells
Salmeterol Xinafoate
carmoterol

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Differential contribution of two serine residues of wild type and constitutively active β2-adrenoceptors to the interaction with β2-selective agonists. / Kikkawa, Hideo; Kurose, Hitoshi; Isogaya, Masafumi; Sato, Yoji; Nagao, Taku.

In: British Journal of Pharmacology, Vol. 121, No. 6, 02.08.1997, p. 1059-1064.

Research output: Contribution to journalArticle

@article{a3f690ee945a45b189bcea0868345974,
title = "Differential contribution of two serine residues of wild type and constitutively active β2-adrenoceptors to the interaction with β2-selective agonists",
abstract = "1. We have studied the difference in receptor binding activity between partial and full β2-adrenoceptor agonists and the abilities of the agonists to interact with Ser204 and Ser207 in the fifth transmembrane region of the β2-adrenoceptor, amino acid residues that are important for activation of the β2-adrenoceptor. 2. In the binding study with [125I]-iodocyanopindolol, the K(i) values of (±)-salbutamol, (±)-salmeterol, TA-2005 and (-)-isoprenaline for the β2-adrenoceptor expressed in COS-7 cell membranes were 3340, 21.0, 12.0 and 904 nM, respectively. The β1/β2 selectivity of these agonists was in the order of (±)-salmeterol (332 fold) > TA-2005 (52.8) > (±)-salbutamol (6.8) > (-)-isoprenaline (1.1), and the β3-/β2-adrenoceptor selectivity of these agonists was in the order of TA-2005 (150 fold) > (±)-salmeterol (88.6) > (±)-salbutamol (10.4) > (-)-isoprenaline (3.2). 3. The maximal activation of adenylyl cyclase by stimulation of the β1-, β2- and β3-adrenoceptors by TA-2005 was 32, 100 and 100{\%} of that by (-)-isoprenaline, respectively, indicating that TA-2005 is a full agonist at the β2- and β3-adrenoceptors and a partial agonist at the β1-adrenoceptor. (±)-Salbutamol and (±)-salmeterol were partial agonists at both β1- (8{\%} and 9{\%} of (-)-isoprenaline) and β2- (83{\%} and 74{\%} of (-)-isoprenaline) adrenoceptors. 4. The affinities of full agonists, TA-2005 and (-)-isoprenaline, were markedly decreased by substitution of Ala for Ser204 (S204A) of the β2-adrenoceptor, whereas this substitution slightly reduced the affinities of partial agonists, (±)-salbutamol and (±)-salmeterol. Although the affinities of full agonists for the S207A-β2-adrenoceptor were decreased, those of partial agonists for the S207A-β2-adrenoceptor were essentially the same as for the wild type receptor. 5. The constitutively active mutant (L266S, L272A) of the β2-adrenoceptor had an increased affinity for all four agonists. The affinities of full agonists were decreased by substitution of Ser204 of the constitutively active mutant, whereas the degree of decrease was smaller than that caused by the substitution of the wild type receptor. Although the affinities of(±)-salbutamol and (±)-salmeterol for the S207A-β2-adrenoceptor were essentially the same as those for the wild type β2-adrenoceptor, the affinities of (±)-salbutamol and (±)-salmeterol for the constitutively active β2-adrenoceptor were decreased by substitution of Ser207. 6. These results suggest that Ser204 and Ser207 of the wild type and constitutively active β2-adrenoceptors differentially interacted with β2-selective agonists.",
author = "Hideo Kikkawa and Hitoshi Kurose and Masafumi Isogaya and Yoji Sato and Taku Nagao",
year = "1997",
month = "8",
day = "2",
doi = "10.1038/sj.bjp.0701229",
language = "English",
volume = "121",
pages = "1059--1064",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Differential contribution of two serine residues of wild type and constitutively active β2-adrenoceptors to the interaction with β2-selective agonists

AU - Kikkawa, Hideo

AU - Kurose, Hitoshi

AU - Isogaya, Masafumi

AU - Sato, Yoji

AU - Nagao, Taku

PY - 1997/8/2

Y1 - 1997/8/2

N2 - 1. We have studied the difference in receptor binding activity between partial and full β2-adrenoceptor agonists and the abilities of the agonists to interact with Ser204 and Ser207 in the fifth transmembrane region of the β2-adrenoceptor, amino acid residues that are important for activation of the β2-adrenoceptor. 2. In the binding study with [125I]-iodocyanopindolol, the K(i) values of (±)-salbutamol, (±)-salmeterol, TA-2005 and (-)-isoprenaline for the β2-adrenoceptor expressed in COS-7 cell membranes were 3340, 21.0, 12.0 and 904 nM, respectively. The β1/β2 selectivity of these agonists was in the order of (±)-salmeterol (332 fold) > TA-2005 (52.8) > (±)-salbutamol (6.8) > (-)-isoprenaline (1.1), and the β3-/β2-adrenoceptor selectivity of these agonists was in the order of TA-2005 (150 fold) > (±)-salmeterol (88.6) > (±)-salbutamol (10.4) > (-)-isoprenaline (3.2). 3. The maximal activation of adenylyl cyclase by stimulation of the β1-, β2- and β3-adrenoceptors by TA-2005 was 32, 100 and 100% of that by (-)-isoprenaline, respectively, indicating that TA-2005 is a full agonist at the β2- and β3-adrenoceptors and a partial agonist at the β1-adrenoceptor. (±)-Salbutamol and (±)-salmeterol were partial agonists at both β1- (8% and 9% of (-)-isoprenaline) and β2- (83% and 74% of (-)-isoprenaline) adrenoceptors. 4. The affinities of full agonists, TA-2005 and (-)-isoprenaline, were markedly decreased by substitution of Ala for Ser204 (S204A) of the β2-adrenoceptor, whereas this substitution slightly reduced the affinities of partial agonists, (±)-salbutamol and (±)-salmeterol. Although the affinities of full agonists for the S207A-β2-adrenoceptor were decreased, those of partial agonists for the S207A-β2-adrenoceptor were essentially the same as for the wild type receptor. 5. The constitutively active mutant (L266S, L272A) of the β2-adrenoceptor had an increased affinity for all four agonists. The affinities of full agonists were decreased by substitution of Ser204 of the constitutively active mutant, whereas the degree of decrease was smaller than that caused by the substitution of the wild type receptor. Although the affinities of(±)-salbutamol and (±)-salmeterol for the S207A-β2-adrenoceptor were essentially the same as those for the wild type β2-adrenoceptor, the affinities of (±)-salbutamol and (±)-salmeterol for the constitutively active β2-adrenoceptor were decreased by substitution of Ser207. 6. These results suggest that Ser204 and Ser207 of the wild type and constitutively active β2-adrenoceptors differentially interacted with β2-selective agonists.

AB - 1. We have studied the difference in receptor binding activity between partial and full β2-adrenoceptor agonists and the abilities of the agonists to interact with Ser204 and Ser207 in the fifth transmembrane region of the β2-adrenoceptor, amino acid residues that are important for activation of the β2-adrenoceptor. 2. In the binding study with [125I]-iodocyanopindolol, the K(i) values of (±)-salbutamol, (±)-salmeterol, TA-2005 and (-)-isoprenaline for the β2-adrenoceptor expressed in COS-7 cell membranes were 3340, 21.0, 12.0 and 904 nM, respectively. The β1/β2 selectivity of these agonists was in the order of (±)-salmeterol (332 fold) > TA-2005 (52.8) > (±)-salbutamol (6.8) > (-)-isoprenaline (1.1), and the β3-/β2-adrenoceptor selectivity of these agonists was in the order of TA-2005 (150 fold) > (±)-salmeterol (88.6) > (±)-salbutamol (10.4) > (-)-isoprenaline (3.2). 3. The maximal activation of adenylyl cyclase by stimulation of the β1-, β2- and β3-adrenoceptors by TA-2005 was 32, 100 and 100% of that by (-)-isoprenaline, respectively, indicating that TA-2005 is a full agonist at the β2- and β3-adrenoceptors and a partial agonist at the β1-adrenoceptor. (±)-Salbutamol and (±)-salmeterol were partial agonists at both β1- (8% and 9% of (-)-isoprenaline) and β2- (83% and 74% of (-)-isoprenaline) adrenoceptors. 4. The affinities of full agonists, TA-2005 and (-)-isoprenaline, were markedly decreased by substitution of Ala for Ser204 (S204A) of the β2-adrenoceptor, whereas this substitution slightly reduced the affinities of partial agonists, (±)-salbutamol and (±)-salmeterol. Although the affinities of full agonists for the S207A-β2-adrenoceptor were decreased, those of partial agonists for the S207A-β2-adrenoceptor were essentially the same as for the wild type receptor. 5. The constitutively active mutant (L266S, L272A) of the β2-adrenoceptor had an increased affinity for all four agonists. The affinities of full agonists were decreased by substitution of Ser204 of the constitutively active mutant, whereas the degree of decrease was smaller than that caused by the substitution of the wild type receptor. Although the affinities of(±)-salbutamol and (±)-salmeterol for the S207A-β2-adrenoceptor were essentially the same as those for the wild type β2-adrenoceptor, the affinities of (±)-salbutamol and (±)-salmeterol for the constitutively active β2-adrenoceptor were decreased by substitution of Ser207. 6. These results suggest that Ser204 and Ser207 of the wild type and constitutively active β2-adrenoceptors differentially interacted with β2-selective agonists.

UR - http://www.scopus.com/inward/record.url?scp=0030740473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030740473&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0701229

DO - 10.1038/sj.bjp.0701229

M3 - Article

C2 - 9249239

AN - SCOPUS:0030740473

VL - 121

SP - 1059

EP - 1064

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -